Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in ...

This corresponds to an absolute risk difference of −4.2% ... lowering HCC risk by 36% (aSHR 0.64), compared with a 21% risk reduction observed with hydrophilic statins such as rosuvastatin ...

coronary revascularisation or hospitalisation for unstable angina – with a 25% relative risk reduction and a 4.8% absolute risk reduction in the first occurrence of major adverse cardiovascular ...